Evaluation of response to radioiodine therapy in thyroid oncocytic carcinoma patients: A single center experience from Iran

Introduction: Thyroid oncocytic carcinoma, also known as Hürthle cell carcinoma (HCC), is a rare subtype of thyroid cancer with unique characteristics. Radioiodine therapy, while less effective for HCC due to poor radioiodine accumulation in tumor, has shown improved survival rates for tumors larger than ۲ cm. Adjuvant radioiodine therapy is recommended in certain cases, particularly for older patients with a worse prognosis.Methods: This study reviewed data from ۱۸ HCC cases compared to the overall patient population (OPP) at our center between ۲۰۱۹ and ۲۰۲۲.Results: The mean age at diagnosis was higher for HCC patients compared to OPP, with varying responses to therapy observed. Assessment of response to therapy after one year revealed ۲۶.۷%, ۲۰%, ۲۰%, and ۳۳.۳% of HCC patients with excellent, indeterminate, biochemical incomplete, and structural incomplete responses, which were ۴۱.۵%, ۲۴.۷%, ۱۳%, and ۲۰.۷% in OPP, respectively. The Kaplan curve of patient survival showed an average of ۱۰۰±۱۳.۵ months.Conclusion: Approximately ۴۴% of HCC patients showed excellent survival outcomes after radioiodine therapy, highlighting its importance as a treatment option for HCC. Further research is needed to optimize treatment choices and improve patient outcomes in this less common subtype of thyroid cancer.

کلیدواژه ها:

Radioiodine ، Thyroid oncocytic carcinoma ، Hürthle cell carcinoma